Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Samineh Sehatbakhsh

Cardiovascular Disease Ocala, FL Medical Doctor

NPI 1801281647 CMS profile 5697942

125 Sw 11Th St, Ocala, FL 34471

Open in the dashboard

General payments

$37,799

129 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Samineh Sehatbakhsh of Ocala, FL is reported in the CMS Open Payments database as having received $37,799 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,533 38
2024 General $2,494 23
2023 General $12,285 16
2022 General $17,186 18
2021 General $517 10
2020 General $563 8
2019 General $1,219 16

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Samineh Sehatbakhsh
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Samineh Sehatbakhsh were reported at $3,533. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Samineh Sehatbakhsh Cardiovascular Disease median Middle half National median
2019 $1,219 $450 $127–$1,392 $163
2020 $563 $242 $77–$751 $114
2021 $517 $335 $101–$1,037 $132
2022 $17,186 $395 $121–$1,211 $149
2023 $12,285 $443 $136–$1,283 $160
2024 $2,494 $450 $136–$1,323 $164
2025 $3,533 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Medtronic, Inc. $17,008 23 payments
  2. Abbott Laboratories $14,670 31 payments
  3. Edwards Lifesciences Corporation $2,146 24 payments
  4. Boston Scientific Corporation $1,104 22 payments
  5. Penumbra, Inc. $1,050 3 payments
  6. Medtronic Vascular, Inc. $765 12 payments
  7. Teleflex LLC $269 2 payments
  8. Astellas Pharma US Inc $224 2 payments
  9. AstraZeneca Pharmaceuticals LP $132 2 payments
  10. Cardiovascular Systems Inc. $119 1 payment
  11. Other $311 7 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Grant $26,250 2 payments
  2. Food and Beverage $7,444 112 payments
  3. Travel and Lodging $4,005 14 payments
  4. Education $99 1 payment
Products named General payments · program years 2019–2025
  1. NAVITOR $2,353 16 payments
  2. COREVALVE EVOLUT R $1,516 16 payments
  3. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $1,490 7 payments
  4. Indigo System $1,050 3 payments
  5. SAPIEN 3 Ultra RESILIA $429 10 payments
  6. WATCHMAN FLX $371 4 payments
  7. MitraClip $325 2 payments
  8. RESOLUTE ONYX $275 2 payments
  9. MANTA $269 2 payments
  10. Omnilink Elite vascular stent system $202 2 payments
  11. Other $2,256 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

135

Median for Interventional Cardiology: 2,236

Drug cost

$1,279

Median for Interventional Cardiology: $380,412

Branded share of claims

69.6%

Median for Interventional Cardiology: 27.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 94 $943
Rosuvastatin Calcium Generic 26 $248
Atorvastatin Calcium Generic 15 $88

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 4,694 Part D prescribers listed as Interventional Cardiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 48 billing codes

Paid by Medicare

$82,486

Medicare's payments for the services billed

Medicare patients

191

Average age 76

Services billed

695

97 women, 94 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 60%
Arthritis 54%
Diabetes 53%
Atrial fibrillation 41%
Chronic kidney disease 41%
Depression 39%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record